Dystroglycan is encoded by a single gene and cleaved into two proteins, a-and P-dystroglycan, by posttranslational processing. The 120-kDa peripheral nerve isoform of a-dystroglycan binds laminin-2 comprised of the a2, /31, and y l chains. In congenital muscular dystrophy and dy mice deficient in laminin a2 chain, peripheral rnyelination is disturbed, suggesting a role for the dystroglycan-laminin interaction in peripheral myelinogenesis. To begin to test this hypothesis, we have characterized the dystroglycan-laminin interaction in peripheral nerve. We demonstrate that (1 ) a-dystroglycan is an extracellular peripheral membrane glycoprotein that links P-dystroglycan in the Schwann cell outer membrane with laminin-2 in the endoneurial basal lamina, and (2) dystrophin homologues Dpl16 and utrophin are cytoskeletal proteins of the Schwann cell cytoplasm. We also present data that suggest a role for glycosylation of a-dystroglycan in the interaction with laminin. Key Words: Dystroglycan-Laminin-Schwann cell-Myelination-Basal lamina. J. Neurochem. 66,151 8-1524 (1 996).
Dystroglycan is encoded by a single gene and cleaved into two proteins, a -and P-dystroglycan, by posttranslational processing (Ibraghimov-Beskrovnaya et al., 1992) . In skeletal muscle, a-dystroglycan with a molecular mass of 156 kDa binds the basal lamina component, laminin (Ibraghimov-Beskrovnaya et al., 1992; Ervasti and Campbell, 1993) , and 0-dystroglycan binds to cytoskeletal proteins dystrophin and utrophin (see Tinsley et al., 1994) . Laminin is a heterotrimer made up of three chains of classes a , p, and y, and exists in numerous trimeric isoforms in different tissues (see Burgeson et al., 1994) . Laminin a chains have globular (G) domain repeats at the C-terminus, and laminin-1, comprised of the a l , p l , and y l chains, binds to a-dystroglycan via the G repeats in the a 1 chain (Gee et al., 1993) . In peripheral nerve, laminin-2, comprised of the a2, p l , and y l chains, is expressed in the endoneurium (Leivo and Engvall, 1988; Sanes et al., 1990) . aDystroglycan with a molecular mass of 120 kDa is ' expressed surrounding peripheral nerve fibers in vivo and binds both laminin-1 and 2 in vitro (Yamada et al., 1994) . Recently, laminin a 2 chain was shown to be deficient in congenital muscular dystrophy and dy mice, which have muscular dystrophy and peripheral dysmyelination (Sunada et al., 1994; Tom6 et al., 1994; Xu et al., 1994) . Furthermore, the expression of laminin in the basal lamina is associated with Schwann cell development (Leivo and Engvall, 1988; Obremski and Bunge, 1995) . These findings suggest a role for the interaction of dystroglycan with laminin in peripheral myelinogenesis. To begin to test this hypothesis, we have characterized the dystroglycanlaminin interaction in peripheral nerve.
MATERIALS AND METHODS

Immunochemical analysis
Immunostaining of cryosections (7 pm) from rabbit sciatic nerve was performed as previously described (Matsumura et al., 1993; Yamada et al., 1994) . Specimens were observed and fluorescent images were obtained on a Zeiss confocal laser scanning microscope (cLSM) model LSM 310, using an argon ion laser (A = 488 nm) (Yamada et al., 1994) . Three to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), immunoblotting, and laminin-blot overlay were performed as described previously (Matsumura et al., 1993; Yamada et al., 1994) .
Monoclonal antibodies IIH6 against a-dystroglycan, 43DAGl8D5 against the C-terminus of 0-dystroglycan, VIA4, against the cysteine-rich1C-terminal domains of dystrophin, and 2D9 against the G domain of human laminin a 2 chain were characterized previously (Ervasti and Campbell, 1993; Cullen et al., 1994; Hori eta] ., 1994). Affinity-purified sheep antibody against dystroglycan fusion protein D (anti-FPD) and affinity-purified rabbit antibody against the Cterminus of utrophin (anti-DRP) were characterized previously (Ibraghimov-Beskrovnaya et al., 1992; Matsumura et al., 1993) . Monoclonal antibodies DYS2 against the Cterminus of dystrophin and DRPl against the C-terminus of utrophin were purchased from Novocastra. Monoclonal antibodies 5H2 against human laminin a2, l l D 5 against human laminin a l , and 4E10 against human laminin 0 1 chains were purchased from GibcoBRL. Monoclonal antibody 15E2E2 against bovine S-100 protein was purchased from Chemicon. Monoclonal antibodies against sialyl Tn and sialyl Lewis A were purchased from Ohtsuka Phamaceutical. Monoclonal antibody anti-HNK-1 and monoclonal antibody against Lewis X were purchased from Becton Dickinson. Monoclonal antibody against sialyl Lewis X was kindly provided by Dr. Nobuo Hanai (Kyowa Hakko Kogyo). Monoclonal antibodies against heparan sulfate and keratan sulfate were purchased from Seikagaku Corporation.
Lectin staining of the nitrocellulose transfers was performed using the following lectins: Peroxidase-labeled wheat germ agglutinin (WGA), concanavalin A (Con A), and Vicia villosa agglutinin isolectin B, (VVA-B4) were purchased from Sigma. Peroxidase-labeled jackfruit agglutinin (Jacalin) was purchased from E-Y Laboratories. Biotin-labeled Phaseolus vulgaris Eq (PHA-E4), Lens culinalis lectin (LCA), Aleuria aurantia lectin (AAL), Lotus tetragonobulus lectin (Lotus), and Ules europaeus agglutinin 1 (UEA-1) were purchased from Seikagaku Corporation. The DIG Glycan Differentiation Kit was purchased from BoehringerMannheim.
Alkaline extraction of crude peripheral nerve membranes
Crude bovine peripheral nerve membranes were suspended at a protein concentration of 2.5 mglml in 50 mM Tris-HC1, pH 7.4, containing a cocktail of protease inhibitors, i.e., benzamidine (0.75 mM), phenylmethylsulfonyl fluoride (PMSF) (0.1 mM), pepstatin A (0.7 pM), aprotinin (76.8 nM), and leupeptin ( 1.1 pM) (buffer A). The suspension was titrated to pH 11, extracted for 1 h at room temperature, and centrifuged at 140,000 g for 30 min at 25°C. The supernatants were titrated to pH 7.4. The pellets were suspended in the original volume of buffer A. The suspension was titrated to pH 12, extracted for 1 h at room temperature, and centrifuged at 140,000 g for 30 min at 2S°C. The supernatants were titrated to pH 7.4. The pellets were suspended in the original volume of buffer A.
Isolation of a-dystroglycan and its associated proteins from crude peripheral nerve membranes
Crude bovine peripheral nerve membranes were extracted at a protein concentration of 5 mglml in 50 mM Tris-HC1, pH 7.4, containing 1 % digitonin, 0.5 M sucrose, 0.5 M NaCl, and the aforementioned cocktail of protease inhibitors for 2 h at 4°C. Digitonin extracts (60 ml) were circulated over 10 ml of WGA-Sepharose (Pharmacia) at 4OC overnight. After extensive wash, the WGA-Sepharose was eluted with buffer B (50 mM Tris-HC1, pH 7.4, 0.1% digitonin, 0.75 mM benzamidine, and 0.1 mM PMSF) containing 0.3 M N-acetylglucosamine (GlcNAc) and 0.5 M sucrose. The eluates were circulated over 1 ml of laminin-Sepharose (Yamada et al., 1994) at 4°C overnight in the presence of 1 mM CaCI, and 1 mM MgCl,. After extensive wash, the larninin-Sepharose was eluted with buffer B containing 10 mM EDTA.
Isolation of a-dystroglycan from crude peripheral nerve membranes
Crude bovine peripheral nerve membranes were suspended at a protein concentration of 5 mglml in buffer A containing 0.5 M NaC1. The suspension was titrated to pH 12, extracted for 1 h at room temperature, and centrifuged at 140,000 g for 30 min at 2S0C. The supernatants were titrated to pH 7.4 and centrifuged at 140,000 g for 30 min at 4°C. WGA-and laminin-affinity chromatographies of the supernatants were performed as described above.
Enzymatic deglycosylation of peripheral nerve a-dystroglycan
Enzymatic deglycosylation of peripheral nerve a-dystroglycan was performed using neuraminidase from Arthrobacter ureafaciens (Nacalai Tesque) , N-glycosidase F from Flavobacterium rneningosepticum (Boehringer-Mannheim) , 0-glycosidase from Diplococcus pneumoniae (BoehringerMannheim), chondroitinase ABC from Proteus vulgaris (Seikagaku), heparinase from Flavobacterium heparinum (Seikagaku), heparitinase from Flavobacterium heparinum (Seikagaku), and keratanase from Pseudomonas species (Seikagaku). For neuraminidase treatment, a-dystroglycan was first made 1% in SDS and incubated at 100°C for 5 min, then diluted 10-fold with concentrated buffer and distilled water to final concentrations of 0.5 M acetate buffer, pH 5.5, 1% Triton X-100, and 0.1% SDS, and incubated with neuraminidase (10 mU/pg of substrate) at 37OC for 24 h. For control, samples were treated identically in the absence of neuraminidase. For treatment with 0-glycosidase, samples were treated identically, but 0-glycosidase (0.25 m u / pg of substrate) was added to the incubation buffer. For Nglycosidase F treatment, a-dystroglycan was first made 1% in SDS and incubated at 100°C for 5 min, then diluted 10-fold with concentrated buffer and distilled water to final concentrations of 50 mM Tris-HC1, pH 7.4, 1% Triton X-100, and 0.1% SDS, and incubated with N-glycosidase F (0.12 Ulpg of substrate) at 37OC for 24 h. For treatment with glycosaminoglycan chain lyases, a-dystroglycan was incubated with enzymes in the following conditions: chondroitinase ABC (50 mU1pg of substrate) in 100 mM TrisHCl, 50 mM acetate buffer, pH 8.0, at 37OC for 2 h; heparinase ( 1 mUlpg of substrate) in 10 mM phosphate buffer,
